Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Epidermal Growth Factor Inhibitors

  • Deepa S. Subramaniam
  • Marion Hartley
  • Michael Pishvaian
  • Ruth He
  • John L. Marshall
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_1931-3

Definition

The EGFR receptor (EGFR) is a member of the HER family of receptor tyrosine kinases that includes EGFR itself (ErbB1/HER1), ErbB2 (HER2/neu), ErbB3 (HER3), and ErbB4 (HER4). These proteins are classic membrane-bound tyrosine kinase receptors whose activation is typically ligand dependent. The principal ligands for EGFR are EGF and TGF-α. Other ligands include amphiregulin, heparin-binding EGF, the poxvirus mitogens, epiregulin, and β-cellulin.

Characteristics

EGFR Activation and Downstream Signaling

Receptor activation results in homo- or heterodimerization and autophosphorylation of c-terminal tyrosine residues. Receptor activation enables the docking of cytoplasmic proteins that bind to specific phosphotyrosine residues and initiate several cell signaling pathways. These pathways include the Ras-Raf-MAPK pathway, the PI3K-AKT pathway, the protein kinase C pathway, the STAT pathway, and the src kinase pathway, all of which play important roles in tumor cell proliferation,...

Keywords

Rectal Cancer National Comprehensive Cancer Network Keyhole Limpet Hemocyanin EGFR Mutation EGFR Activation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R, Barbachano Y, Oates J, Chau I (2012) Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol 30(14):1620–1627. doi:10.1200/JCO.2011.39.6036. Epub 2 Apr 2012CrossRefPubMedGoogle Scholar
  2. Eberhard DA, Johnson BE, Amler LC et al (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23:5900CrossRefPubMedGoogle Scholar
  3. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epithelial growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129CrossRefPubMedGoogle Scholar
  4. Marshall J (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107(6):1207–1218CrossRefPubMedGoogle Scholar
  5. Price TJ et al (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15(6):569–579CrossRefPubMedGoogle Scholar
  6. Primrose J et al (2014) Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15(6):601–611CrossRefPubMedGoogle Scholar
  7. Ramalingam SS et al (2015) AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): results from a phase 1 expansion cohort. J Clin Oncol 33 (suppl): abstr 8000Google Scholar
  8. Reardon DA, Schuster J, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Desjardins A, Ashby LS, Duic JP, Mrugala MM, Werner A, Hawthorne T, He Y, Green JA, Yellin MJ, Turner CD, Davis TA, Sampson JH, The ReACT Study Group (2015) ReACT: Overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. J Clin Oncol 33(15):2009Google Scholar
  9. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH (2015) A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 17(6):854–861CrossRefPubMedPubMedCentralGoogle Scholar
  10. Sequist LV et al (2015) Rociletinib in EGFR-mutated non–small-cell lung cancer. N Engl J Med 372:1700–1709. doi:10.1056/NEJMoa1413654CrossRefPubMedGoogle Scholar
  11. Shepherd Frances A et al (2005) Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med 353:123–132CrossRefPubMedGoogle Scholar
  12. Stasi I, Cappuzzo F (2014) Second generation tyrosine kinase inhibitors for the treatment of metastatic non-small-cell lung cancer. Transl Resp Med 2:2. doi:10.1186/2213-0802-2-2CrossRefGoogle Scholar
  13. Taieb J et al (2014) Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 15(8):862–873CrossRefPubMedGoogle Scholar
  14. Tournigand C et al (2015) Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol. doi: 10.1016/S1470-2045(15)00216-8. Published online 13 Oct 2015Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  • Deepa S. Subramaniam
    • 1
  • Marion Hartley
    • 2
  • Michael Pishvaian
    • 3
  • Ruth He
    • 3
  • John L. Marshall
    • 3
  1. 1.Georgetown University HospitalWashingtonUSA
  2. 2.Ruesch Center for the Cure of Gastrointestinal CancersLombardi Comprehensive Cancer Center, Georgetown UniversityWashingtonUSA
  3. 3.Lombardi Comprehensive Cancer Center, Georgetown UniversityWashingtonUSA